Akero Therapeutics, Inc. Company Information

Akero Therapeutics, Inc.'s employee growth, exchange listings and data sources

Key Information

Name: Akero Therapeutics, Inc.
Ticker: AKRO
Exchange: NasdaqGS
Founded: 2017
Industry: Biotechnology
Sector: Pharmaceuticals & Biotech
Market Cap: US$1.993b
Shares Outstanding: 69.80m
Website: https://akerotx.com

Number of Employees

Location

Akero Therapeutics, Inc.
601 Gateway Boulevard
Suite 350
South San Francisco
California
94080
United States

Listings

Ticker	Exchange	Primary Security	Security Type	Country	Currency	Listed on
AKRO	NasdaqGS (Nasdaq Global Select)	Yes	Common Stock	US	USD	Jun 2019
0K4	DB (Deutsche Boerse AG)	Yes	Common Stock	DE	EUR	Jun 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
Data	Last Updated (UTC time)
Company Analysis	2024/12/26 01:15
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 01:15
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akero Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason Zemansky	BofA Global Research
Alexandria Hammond	BofA Global Research
Edward Nash	Canaccord Genuity